Login to Your Account



Clinic Roundup


Thursday, June 16, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported promising median overall survival of 12.4 months from a Phase II trial of bavituximab plus carboplatin and paclitaxel in metastatic non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription